Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Technical Officer | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,915 |
Ending reported balance
After 2026-08-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-13 · Exercise / conversion · Acquired 2,024 · Balance 20,994 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. Row 2 · 2026-08-13 · Sale · Disposed 5,079 · Balance 15,915 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 5,945 |
Reported balance
After 2026-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-13 · Exercise / conversion · Disposed 2,024 · Balance 5,945 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,024 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001649904-26-000015 · form4.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,945 Underlying: Common Stock · 2,024 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. F2 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,079 | $119.75 | $608,210.25 |
DisclosureSEC source: 0001649904-26-000015 · form4.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,915 F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,024 | $6.80 | $13,763.20 |
DisclosureSEC source: 0001649904-26-000015 · form4.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $98.47 | $0.00 |
DisclosureSEC source: 0001104659-26-015405 · tm266366-7_4seq1.xml · derivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2036-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015405 · tm266366-7_4seq1.xml · derivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · derivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 4,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 6,507 | $108.99 | $709,197.93 |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,970 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 16,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009769 · tm264963-7_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,748 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-25-105576 · tm2530076-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,748 shares Expires 2031-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,748 | $115.24 | $1,123,397.54 |
DisclosureSEC source: 0001104659-25-105576 · tm2530076-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.00 to $115.73 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 9,748 | $30.66 | $298,873.68 |
DisclosureSEC source: 0001104659-25-105576 · tm2530076-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 721 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-25-104437 · tm2529785-1_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,748 Underlying: Common Stock · 721 shares Expires 2031-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,094 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-104437 · tm2529785-1_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,563 Underlying: Common Stock · 2,094 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,815 | $115.01 | $323,750.05 |
DisclosureSEC source: 0001104659-25-104437 · tm2529785-1_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.00 to $115.08 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 721 | $30.66 | $22,105.86 |
DisclosureSEC source: 0001104659-25-104437 · tm2529785-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,094 | $27.35 | $57,270.90 |
DisclosureSEC source: 0001104659-25-104437 · tm2529785-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 12,344 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · derivative · entry 7 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,469 Underlying: Common Stock · 12,344 shares Expires 2031-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,093 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · derivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,657 Underlying: Common Stock · 2,093 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,412 | $112.81 | $384,907.72 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · nonDerivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.51 to $113.14 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 8,332 | $112.06 | $933,645.59 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · nonDerivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,921 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.50 to $112.48 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,693 | $110.95 | $298,783.50 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,253 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $110.23 to $111.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 12,344 | $30.66 | $378,467.04 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,093 | $27.35 | $57,243.55 |
DisclosureSEC source: 0001104659-25-100851 · tm2529018-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 14,687 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-25-087487 · tm2525191-1_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,813 Underlying: Common Stock · 14,687 shares Expires 2031-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,094 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-087487 · tm2525191-1_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,750 Underlying: Common Stock · 2,094 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 16,781 | $105.30 | $1,767,005.74 |
DisclosureSEC source: 0001104659-25-087487 · tm2525191-1_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.82 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 14,687 | $30.66 | $450,303.42 |
DisclosureSEC source: 0001104659-25-087487 · tm2525191-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,094 | $27.35 | $57,270.90 |
DisclosureSEC source: 0001104659-25-087487 · tm2525191-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,188 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-082668 · tm2524281-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,844 Underlying: Common Stock · 4,188 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,188 | $100.07 | $419,090.65 |
DisclosureSEC source: 0001104659-25-082668 · tm2524281-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.00 to $100.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,188 | $27.35 | $114,541.80 |
DisclosureSEC source: 0001104659-25-082668 · tm2524281-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,984 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-077706 · tm2523328-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,969 Underlying: Common Stock · 3,984 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,984 | $90.08 | $358,891.47 |
DisclosureSEC source: 0001104659-25-077706 · tm2523328-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $90.00 to $90.27 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,984 | $6.80 | $27,091.20 |
DisclosureSEC source: 0001104659-25-077706 · tm2523328-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,969 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-067430 · tm2520691-3_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,953 Underlying: Common Stock · 7,969 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,985 | $80.00 | $318,800.00 |
DisclosureSEC source: 0001104659-25-067430 · tm2520691-3_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,984 | $75.56 | $301,050.56 |
DisclosureSEC source: 0001104659-25-067430 · tm2520691-3_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,494 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $75.12 to $75.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,969 | $6.80 | $54,189.20 |
DisclosureSEC source: 0001104659-25-067430 · tm2520691-3_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 02:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,228 | $57.22 | $70,266.16 |
DisclosureSEC source: 0001104659-25-015324 · tm257103-7_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,509 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015324 · tm257103-7_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 4,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015324 · tm257103-7_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015324 · tm257103-7_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-02-13 F4 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015324 · tm257103-7_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7 | $57.09 | $399.63 |
DisclosureSEC source: 0001104659-25-014259 · tm256729-2_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,612 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 462 | $56.39 | $26,052.18 |
DisclosureSEC source: 0001104659-25-014259 · tm256729-2_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,619 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · derivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3 | $57.54 | $172.62 |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · nonDerivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6.081 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.